1999
DOI: 10.1097/00000478-199901000-00009
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Although the significance of various prognostic factors, such as tumor size and mitotic index (MI), has been well established for smooth-muscle tumors of the stomach, the significance of these factors in other sites is less well defined. We studied 1004 patients with gastrointestinal smooth-muscle tumors for whom vital status could be determined. The average MI and tumor size varied significantly among the five major sites examined: esophagus (53 cases), stomach (524 cases), small bowel 252 cases), colon/rectu… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

21
362
3
42

Year Published

2000
2000
2015
2015

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 585 publications
(428 citation statements)
references
References 30 publications
21
362
3
42
Order By: Relevance
“…Tumor-associated mortality was significantly higher in the patients with their primary GIST arising in the small intestine when compared with the stomach (35 vs. 18%). 21,40,41 In a large study of over 100 sporadic GISTs, the most sensitive mutation to IM therapy was exon 11 (83.5% response rate) followed by exon 9 (47.8% response rate) and that patients with exon 11 mutations had longer overall survival on imatinib therapy. 42 However, it remains unclear as to whether the site of mutation in the KIT gene or the site of the primary GIST is the most important predictor of response to IM therapy in the setting of germ-line KIT mutation.…”
Section: Discussionmentioning
confidence: 99%
“…Tumor-associated mortality was significantly higher in the patients with their primary GIST arising in the small intestine when compared with the stomach (35 vs. 18%). 21,40,41 In a large study of over 100 sporadic GISTs, the most sensitive mutation to IM therapy was exon 11 (83.5% response rate) followed by exon 9 (47.8% response rate) and that patients with exon 11 mutations had longer overall survival on imatinib therapy. 42 However, it remains unclear as to whether the site of mutation in the KIT gene or the site of the primary GIST is the most important predictor of response to IM therapy in the setting of germ-line KIT mutation.…”
Section: Discussionmentioning
confidence: 99%
“…They postulated that these lesions display various lines of differentiation reflecting the various elements of the gut wall (e.g., muscle, autonomic nerve) and proposed the term (gastrointestinal) stromal tumor (GIST). Over the past few years, it has become increasingly apparent that these tumors need to be studied on a sitespecific basis because of differences in behavior (2,9) and that malignancy is best described in terms of risk factors (10). Although numerous studies have addressed these issues in GIST (11)(12)(13)(14)(15)(16)(17)(18)(19)(20), there has been no study of those rare stromal tumors that develop outside the gastrointestinal tract in the soft tissues of the abdomen with respect to histologic features that predict outcome.…”
mentioning
confidence: 99%
“…The most common site is the stomach followed by the small intestine, rectum, and colon. [1][2][3] Occasionally, primary GISTs have been reported outside the gastrointestinal tract, specifically in the omentum, mesenteries, and retroperitoneum. 4,5 Histologically, these neoplasms are usually composed of spindle cells (70%) or less frequently of epithelioid (20%) or mixed, epithelioid and spindle cell types (10%).…”
mentioning
confidence: 99%